Disease Models & Mechanisms (DMM) is an Open Access biomedical research journal advancing novel insight into the mechanism, diagnosis and therapy of human disease.
DMM is committed to publishing rigorously peer-reviewed research in disease biology that has significant translational impact at the interface of basic and clinical science. Our content is freely available to our communities of basic and clinical researchers, health professionals, patients and their advocates and families. DMM is interdisciplinary in scope, and covers a diverse range of diseases. We also publish cutting-edge techniques and resources that advance the disease biology field.
DMM is led by an international team of expert research-active Editors, including Editor-in-Chief Liz Patton and Deputy Editor-in-Chief Elaine Mardis, and supported by an outstanding Editorial Advisory Board.
DMM included in Read & Publish agreements
DMM is included in many of the Read & Publish agreements offered by The Company of Biologists. This enables discounted or fee-free publication of an uncapped number of Research or Resource articles in DMM for corresponding authors at participating institutions (including, among others, the Max Planck Digital Library and University of California).
Read more about the ways in which DMM is working to increase accessibility for both authors and readers in an Editorial from Editor-in-Chief Liz Patton.
2023 DMM Journal Meeting - Registration now open!
Infectious Diseases Through an Evolutionary Lens
Early-bird registration is now open for the 2023 DMM Journal Meeting 'Infectious Diseases Through an Evolutionary Lens', organised by Wendy Barclay, Sara Cherry, David Tobin and Russell Vance. View our fantastic line up of speakers and register here.
The shifting culture of the scientific workforce – a change for women and girls in science
To mark the International Day of Women and Girls in Science, DMM Editorial Board member Kirsten Sadler discusses the shifting culture of the scientific workforce.
The future of sickle cell disease therapeutics rests in genomics
Ambroise Wonkam discusses how exploring the genomics of sickle cell disease could help identify new therapeutic targets, and further our understanding of genetic risk and the treatment of associated cardiovascular complications.
New advances in CRISPR/Cas-mediated precise gene-editing techniques
CRISPR/Cas technology can effectively disrupt gene function by generating insertions and deletions, but precise gene editing remains challenging. Chris Richardson, Robert Kelsh and Rebecca Richardson discuss recent advances in this field.
Mouse models of fragile X-related disorders
Rob Willemsen and R. Frank Kooy review mouse models of fragile X-related disorders and discuss their advantages, limitations and use as preclinical models, as well as the challenges that remain to improve the reproducibility and translational value of these models.
A novel class of sulphonamides potently block malaria transmission by targeting a Plasmodium vacuole membrane protein by Sabrina Yahiya, Charlie N. Saunders, Sarah Hassan, Ursula Straschil, Oliver J. Fischer, Ainoa Rueda-Zubiaurre, Silvia Haase, Gema Vizcay-Barrena, Mufuliat Toyin Famodimu, Sarah Jordan, Michael J. Delves, Edward W. Tate, Anna Barnard, Matthew J. Fuchter and Jake Baum
Baum and colleagues describe how a new class of antimalarials based on a N-[(4-hydroxychroman-4-yl)methyl]-sulphonamide scaffold potently prevents malaria parasite transmission to the mosquito by targeting the Plasmodium falciparum vacuole membrane protein Pfs16.
In addition, Nicola Blum and Matthew Harris describe how overproliferation of pre-chondrogenic cells carrying a somatic oncogenic mutation in AKT1 or PIK3CA cause a heterochronic shift in long bone formation and skeletal gigantism.